Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Risk assessment and aspirin use in Asian and Western populations

Authors Runlin Gao, Xiaoying Li

Published 14 October 2010 Volume 2010:6 Pages 943—956

DOI https://doi.org/10.2147/VHRM.S9400

Review by Single-blind

Peer reviewer comments 2

Runlin Gao1, Xiaoying Li2

1Department of Cardiology, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing; 2Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China
Objective: The aim of this review was to examine aspirin utilization, cardiovascular risk ­estimation, and clinical evidence for aspirin prophylaxis in Asian versus Western countries.
Methods: A literature search was performed using PubMed and the key terms "aspirin" and "Asia" or "Western".
Results: Despite the growing burden of cardiovascular disease (CVD), aspirin is underutilized in high-risk patients in both Asian and Western countries. A number of risk estimation scores are available; however, validation is needed in countries such as Japan, India, and in South Asia. Underutilization of aspirin in Asia may be linked to an overestimation of bleeding risks. It is possible that a higher prevalence of Helicobacter pylori infection and genetic differences may make Asians more susceptible to gastrointestinal bleeding. Very low aspirin doses and even the wider use of gastroprotective agents may be the optimal approach to high-risk patients in Asia.
Conclusions: Based on the current evidence, aspirin should be used for CVD prevention when the risk:benefit ratio is favorable. A number of trials are underway, including the Diabetic Atherosclerosis Prevention by Cilostazol and Japanese Primary Prevention Project, which will provide key data on the benefits of aspirin in Asian patients at risk of CVD, and may improve aspirin utilization and risk estimation.

Keywords: aspirin, cardiovascular risk estimation, Asia, Western

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies

Eric Bateman, Dave Singh, David Smith, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:197-208

Published Date: 9 June 2010

Readers of this article also read:

Percutaneous coronary intervention of a single coronary artery arising from the right sinus of Valsalva

Mehmet Akif Cakar, Ersan Tatli, Bilhan Ozalp, et al

Vascular Health and Risk Management 2010, 6:1077-1078

Published Date: 25 November 2010

Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells

Myriam Iglewski, Stephen R Grant

Vascular Health and Risk Management 2010, 6:723-734

Published Date: 11 August 2010

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo

Vascular Health and Risk Management 2010, 6:671-690

Published Date: 5 August 2010

Management of high-risk popliteal vascular blunt trauma: clinical experience with 62 cases

Ali Pourzand, Bassir A Fakhri, Ramin Azhough, et al

Vascular Health and Risk Management 2010, 6:613-618

Published Date: 14 July 2010

Mid-term outcomes of patients with PCI prior to CABG in comparison to patients with primary CABG

Sandra Eifert, Helmut Mair, Anne-Laure Boulesteix, et al

Vascular Health and Risk Management 2010, 6:495-501

Published Date: 29 June 2010

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid

Elisavet Moutzouri, Anastazia Kei, Moses S Elisaf, et al

Vascular Health and Risk Management 2010, 6:525-539

Published Date: 29 June 2010

Influence of demographic and metabolic variables on forearm blood flow and vascular conductance in individuals without overt heart disease

Thiago E Sartori, Rafael AB Nunes, Gisela T da Silva, et al

Vascular Health and Risk Management 2010, 6:431-437

Published Date: 31 May 2010

Heart rate control with adrenergic blockade: Clinical outcomes in cardiovascular medicine

David Feldman, Terry S Elton, Doron M Menachemi, et al

Vascular Health and Risk Management 2010, 6:387-397

Published Date: 24 May 2010

Predictors of obstructive sleep apnea in males with metabolic syndrome

Nikolaos Papanas, Paschalis Steiropoulos, Evangelia Nena, et al

Vascular Health and Risk Management 2010, 6:281-286

Published Date: 20 April 2010